Positron Corporation (POSC)

[crammerfool]

More from 2008: POSC At .11 Up 100%.Since.Profile.Launch

http://stockreads.com/Stock-Newsletter.aspx?id=301

POSC At .11 Up 100% Since Profile Launch

6/20/2008 10:23 AM Penny Stocks by: Shazam Stocks

Positron Corp.

(OTCBB: POSC) View Profile Press Release Source: Positron Corporation Positron Corporation Receives Positive Feedback at Society of Nuclear Medicine Meeting Thursday June 19, 12:05 pm ET HOUSTON--(BUSINESS WIRE)--Positron Corporation (OTC: POSC - News) (the ?Company?) recently displayed their molecular imaging and automated radioisotope dose drawing systems at the Society of Nuclear Medicine Meeting in New Orleans, Louisiana. Approximately 3,900 attendees and over 180 exhibiting companies attended the meeting. The Society of Nuclear Medicine meeting is the world`s largest event focused exclusively on the latest developments in molecular imaging technology and nuclear medicine based products and services.

"We received a great deal of positive feedback on our recent acquisition of Dose Shield Corporation and the integration of our product portfolio under one brand allowing for the sale of a turn-key solution encompassing imaging system, dose dispensing system, radiopharmaceutical and disease management software," stated Joe Oliverio, President of Positron. ?Of particular note,? continued Mr. Oliverio, ?potential customers were pleasantly surprised to hear of our upcoming market release of an economically priced PET system that is design optimized for cardiology applications We are not aware of any other company selling a PET only into the USA market. We look forward to meeting the demand for a more economical product in cardiac PET, and our goal is to be delivering devices immediately after receiving our FDA 510k approval.? About Positron Corporation Positron Corporation is a growing healthcare company offering cardiac molecular imaging solutions that will transform the delivery of healthcare through radiopharmaceutical development, advancing imaging technology and by introducing unique disease management applications into the market. Positron Corporation designs, manufactures and sells SPECT, PET and automated dose delivery devices in to the Nuclear Medicine market. Additional information may be found at http://www.positron.com/.

Forward-Looking Statements This press release contains forward-looking statements that reflect the Company`s current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Positron Corporation are ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company`s research and development efforts, the availability of adequate financing and other uncertainties described in the ?Management?s Discussion and Analysis? section of the Company?s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For any additional information contact Positron?s President, Joe Oliverio at [phone].

Contact:

Positron Joe Oliverio at [phone] -------------------------------------------------------------------------------- Overview Positron Medical Systems (the "Company") is a growing healthcare company offering cardiac molecular imaging solutions that will transform the delivery of healthcare through radiopharmaceutical development, advancing medical imaging technology and by introducing unique disease management applications into the market. The company?s molecular imaging systems incorporate patented and proprietary software and hardware technology for the diagnosis and treatment of patients with heart disease. Through the recent acquisition of Dose Shield, Inc., Positron Medical Systems will now be able to offer a unique combination of low cost medical imaging technology, affordable radiopharmaceutical solutions and disease specific programs / software differentiating themselves from all other medical device manufacturers.

A substantial change in the market landscape is occurring. These changes involve product mix, regulatory requirements, and the expiration of patents on lucrative protected radiopharmaceutical products.

Positron?s software, equipment and drugs are all focused on cardiology, the largest segment of Nuclear Medicine.

The reoccurring revenue generated each year by the US nuclear cardiology market for radiopharmaceuticals is in excess of $1.2 Billion. Five year revenue potential by adding radiopharmaceuticals to the equipment sale are $1.7M / SPECT customer and $2.5M / PET customer. Positron expects to sell greater than 200 SPECT and 300 PET devices. The market for Nuclear Pharm-Assist® sold to existing radiopharmacies and hospitals as well as selling the Cardio-Assist into the cardiologist practice approaches 10,000 targets. Positron will focus on further expanding its ability to compete with other imaging device vendors as well as increase its ability to generate reoccurring revenue at higher margins.

Nuclear Pharm-Assist® by NukeMed, Inc. offers unique delivery methods by creating a first time virtual pharmacy in-house for customers. As part of Positron expanding into providing pharmaceuticals with the Nuclear Pharm-Assist® automated dispensing device, the company will leverage its knowledge of the FDA and begin to manufacture the primary radioactive drugs prescribed in nuclear cardiology such as Tc-99m generators, Rb-82 generators and Thallium 201.

Positron Medical is addressing the needs of the cardiac molecular imaging market. The Company`s joint venture Neusoft Positron Medical Systems Co. Ltd. based in Shenyang, People`s Republic of China provides Positron Medical a cardiac Positron Emission Tomography (PET) imaging system that can be priced below all competitors. . Positron Medical Systems also offers a competitively priced Single Photon Emission Computed Tomograhy (SPECT) imaging system. The PET and SPECT imaging devices complement each other and positions Positron Medical Systems to capture reoccurring revenue by selling generic radiopharmaceuticals that are the result of recent patent expirations of two key PET and SPECT radiopharmaceuticals. Positron Medical has acquired unique expertise and technology through their acquisition of Dose Shield, Inc. to directly expedite the company?s entry into the radiopharmaceutical market. Combining the sale of these radiopharmaceuticals to the customer with Positron Medical proprietary imaging technologies greatly expands the Company?s ability to capture a significant amount of recurring revenue per sale that greatly exceeds an equipment sale by itself.

Positron is currently developing a coronary disease reversal and prevention online management & solution program. This was made possible by Positron?s agreement with Dr. K. Lance Gould and the University of Texas for exclusive rights to Dr. Gould?s heart disease reversal diet and comprehensive practice management, patient centric program. The Company believes that its online coronary disease reversal and prevention product will provide a solution for patients, insurers, self insured corporations and thousands of community hospitals looking to differentiate their services, save cost and reducing outward migration of patients to the larger hospitals.

Investment Highlights:

Early stage of new marketplace created by a market dynamic shift Only full solutions provider of PET/SPECT/Pharma/Disease management/Solid state Undervalued market capitalization Clinically experienced management with proven market success Opportunity through NukeMed to capitalize on radiopharmaceutical business and off patent tracers First time in nuclear cardiology history that the most prescribed radiopharmaceuticals are going generic JV with Neusoft for Chinese manufacturing and development Contact Information Positron Corp.

1304 Langham Creek Dr #300 Houston, TX 77084 Phone: [phone] Toll Free: [phone] Fax: [phone] Email: [e-mail] Website: www.positron.com -------------------------------------------------------------------------------- Profiles is a special advertising section presented by Shazamstocks.com. All material listed within http://shazamstocks.com/profiles/index.php ("Profiles") was based upon information supplied by the company or from other sources believed to be reliable. The information contained Profiles is not guaranteed by Profiles to be accurate and should not considered to be all-inclusive. The companies discussed on Profiles except for those companies that appear on the URL http://shazamstocks.com/profiles/index.php have not approved the statements made herein. Any discussions and pages contain forward looking statements that involve risks and uncertainties. A company`s actual results could differ materially from those described in any forward - looking statements or announcements discussed on Profiles. We have been compensated by positron 1.5 million rule 144 restricted shares for publication of this profile. All material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Profiles is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst, or underwriter. Companies profiled at URL http://shazamstocks.com/profiles/index.php are ineligiable for recommendations on URL http://www.shazamstocks.com for 90 days following final disposition of any compensation.

-------------------------------------------------------------------------------- This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies` annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Shazamstocks Inc undertakes no obligation to update such statements.

CONTACT: Ken Weiner Tel: [phone] e-mail: [e-mail] Shazamstocks Inc | 125 South state Road 7 Suite 104-221 | Palm Beach | FL | 33411